First Patient Treated in Microbion’s Phase IIA Orthopaedic Infection Trial

Microbion enrolled the first patient in its U.S. Phase IIA study of MBN-101 candidate for treatment of orthopaedic implant-related infections.

MBN-101 is the lead in a new class of drugs under development by Microbion to combat infections, including multi-drug-resistant strains. The study is partially funded by a grant from the U.S. Department...

document icon

You’ve reached your limit.

We’re glad you’re finding value in our content — and we’d love for you to keep going.

Subscribe now for unlimited access to orthopedic business intelligence.

JV

Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.



Contact Us

0